98%
921
2 minutes
20
Background: Bronchiolitis due to respiratory syncytial virus (RSV) is the leading cause of hospitalization among American infants. The overall burden of RSV among infants has been historically under-estimated due to variable testing practices, particularly in the outpatient setting. Universal masking and social distancing implemented during the coronavirus disease 2019 (COVID-19) pandemic altered RSV seasonality, however potential consequences on RSV testing practices across different healthcare settings and sociodemographic groups have not been described. Variable testing practices could also affect accurate assessment of the effects of two recently approved RSV preventative agents targeting infants.
Methods: Utilizing real-time clinical and viral surveillance, we examined RSV testing practices among infants with bronchiolitis within four United States healthcare systems across different healthcare settings and sociodemographic groups pre- and post-COVID-19.
Results: RSV testing among infants with bronchiolitis increased since 2015 within each healthcare system across all healthcare settings and sociodemographic groups, with a more dramatic increase since the COVID-19 pandemic. Outpatient testing remained disproportionately low compared to hospital-based testing, although there were no major differences in testing frequency among sociodemographic groups in either setting.
Conclusions: Although RSV testing increased among infants with bronchiolitis, relatively low outpatient testing rates remain a key barrier to accurate RSV surveillance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.annepidem.2024.04.010 | DOI Listing |
J Infect Public Health
September 2025
Graduate School of Media and Governance, Keio University, 5322, Endo, Fujisawa, Kanagawa 252-0882, Japan. Electronic address:
Objective: To evaluate whether a machine learning (ML) based screening algorithm can optimize respiratory syncytial virus (RSV) testing while maintaining high diagnostic accuracy in pediatric patients.
Study Design: We conducted a retrospective analysis of pediatric patients under 2 years old who presented with respiratory infection symptoms and received RSV testing at Yokohama Municipal Citizen's Hospital (2009-2015). The cohort was divided into training (2009-2013; n = 3587) and validation (2014-2015; n = 587) sets.
J Microbiol Immunol Infect
September 2025
Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan.
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and young children. The COVID-19 pandemic significantly disrupted global RSV epidemiology. This study aimed to investigate the impact of the pandemic on RSV epidemiology in northern Taiwan from 2018 to 2023.
View Article and Find Full Text PDFBMJ Open
September 2025
Microbiology Laboratory, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
Objectives: Globally, the circulation of influenza and other seasonal respiratory viruses changed dramatically during the COVID-19 pandemic. This study aims to determine the trends of acute respiratory infections (ARIs) caused by SARS-CoV-2, influenza A, influenza B and respiratory syncytial viruses (RSVs) in patients presenting to hospitals in the Lao People's Democratic Republic (PDR) (Laos).
Design: Prospective surveillance study.
Am J Trop Med Hyg
September 2025
Department of Tropical Medicine and Infectious Diseases, Tulane University Celia, Scott Weatherhead School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children under 5 years of age, resulting in significant morbidity and mortality worldwide. The aim of the current study is to investigate the prevalence and clinical features of RSV disease in hospitalized infants in Sierra Leone. A prospective study was conducted on children under 2 years of age who were hospitalized at Kenema Government Hospital between October 1, 2020, and January 31, 2023.
View Article and Find Full Text PDFNAR Mol Med
July 2025
Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada.
The therapeutic value of antiviral nucleoside analogs was highlighted during the coronavirus disease 2019 (COVID-19) pandemic, with remdesivir and molnupiravir repurposed for their broad-spectrum antiviral activity. The cytidine analog azvudine (FNC) has recently gained attention as a potential treatment for human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Considering the distinct substrate specificities of HIV-1 reverse transcriptase (RT) and SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), a unifying mechanism of inhibition remains elusive.
View Article and Find Full Text PDF